MRNA Moderna Inc

$MRNA $IBRX part 2 ~ Vaccines ~ Lynch Syndrome / Off-the-Shelf Neoantigen Vaccines: ImmunityBio has developed off-the-shelf neoantigen vaccines (such as ETBX-051 / Tri-Ad5 combinations) targeting common tumor driver mutations (like CEA, MUC1, and Brachyury). These aim to prevent cancer recurrence or intercept disease progression in high-risk hereditary groups (such as Lynch Syndrome patients). Synergy with ANKTIVA (IL-15 Superagonist): Ibrx's broader Triangle Strategy or Cancer BioShield approach, these viral vaccines do not operate in isolation. The viral vaccine introduces the target antigens to trigger antigen-presenting cells, while ANKTIVA acts as the engine—boosting and expanding NK cells and CD8+ memory T-cells to execute a long-lasting cytotoxic immune response. Unlike Modernas vaccine, it doesnt give you cancer and other dangerous side effects.

$MRNA +600% YTD for a company that should be seeing the largest class action suit in the history of modern medicine.

$MRNA $IBRX 's approach to cancer vaccines differs from traditional preventative vaccines. Rather than preventing an initial infection, these are therapeutic vaccines designed to train the patients immune system to recognize, target, and destroy existing cancer cells throughout the body. Key components of Ibrx cancer vaccine platform include: (Ad5 Platform): Ibrx uses engineered, second-generation Human Adenovirus Serotype 5 (Ad5) vectors to deliver tumor-specific antigens directly into immune cells. The vector is modified to minimize pre-existing immunity to the virus itself, allowing it to be administered multiple times effectively.effectively. IBRX-042 (HPV-Associated Cancers): A targeted therapeutic cancer vaccine candidate specifically designed to treat cancers driven by Human Papillomavirus (such as cervical, head and neck, and anal cancers). It works by delivering target viral oncogenic proteins to activate T-cells against HPV-infected malignant cells.

$MRNA looks seriously stretched here. It’s gone from roughly $60 in August to $225, and price is now testing the top of this rising channel after a near-vertical move. Fundamentally, it’s still deeply unprofitable; billions in losses, negative cash flow and revenue nowhere near supporting this valuation. Wall Street’s average target remains well below current levels, sitting at around a $123 average. Nasdaq-100 inclusion created forced buying, not better fundamentals. With Oct. 24 expectations now sky-high, a pull back/consolidation from here looks completely reasonable. Short with a $218 average and aiming for one of the blue supports before I consider profiting, and flipping to a purchase 🤝

$MRNA here we go again .. same crooks with covid vaccine that to this day ppl are complaining about side effects and heart issues .. lawsuits upon lawsuits.. yeah they gonna cure "cancer" gfto.. fool me once fool me twice routine..

$MRNA stock moving like they cured all cancer when all they did was develop a drug for melanoma that works ≈ 20% better in combination with keytruda than keytruda alone, in a small trial of 150 patients. Keytruda is still doing the heavy lifting if you actually peer into the studies. Regardless of that, Moderna’s expiremental drug definitely has clinical significance, but the market has wildly overpriced the stock based to the point where it’s laughable. Constantly running up on stupid headlines like a nothing burger “Russian plague” and “NIH focusing on cancer vaccines” , it’s time for a real correction imo.

$MRNA i might be wrong....but there doesnt appear to be shizzle to bounce off of here i think not yet

$MRNA Moderna jumped 14.1% to about $225 on its first day in the Nasdaq-100, a new 52-week high. Its value is now about $90B, or 40× sales, its highest multiple since I started tracking and about 8× the peer median. This is absolute non-sense and pure manipulation. Moderna’s CEO, Stéphane Bancel, owns ~8% of the company (incl. options), now a ~$7B stake. The business hasn’t cured cancer yet, nor turned a profit since 2022, but the stock has already made him a fortune.

$MRNA $SLS is Next. Onureg / BAT for the SLS Phase 3 Control Arm - 24.7 Month MOS GPS AML Cancer VACCINE Phase 2 MOS - not reached > greater than 67.6 months. it is a No Brainer ... Investment Opportunity of a lifetime. Phase 3 Results Now Imminent.

$MRNA couldn’t help but short this bump. Quarter over quarter declining revenue. Easy short.

$MRNA But, but... Citigroup set a price target of $80 for the company that's inventing a cancer cure 😂😂😂🤡🤡🤡

$MRNA are people really that dumb remember you got the COVID shot and then you got COVID 1 or 2 times or maybe even more and some people died not from COVID but . . . What they didn't tell you.

$MRNA bulls, here is your chance to buy more on this pullback imagine buying here after a 200% plus run on lies/pure manipulation i add seriously consider adding here. its the investment of a lifetime. diamond hands. not selling for a penny under $500

$MRNA I hope the bulls who seems to have bought at $40-60 and enjoyed a hefty 500-600% run, don't mind a modest 30-40% pullback.

$MRNA Closing in on a 100 Billion dollar market cap in the same league as Pharma companies like GSK and Sanofi. 2 highly profitable companies. Friday was forced buying. I call it waterboarding. Passive funds must buy!! Or else!!

$MRNA wicked over the 5min opening range high and couldn’t close a candle over it. Come get your Moderna shares at a $90B valuation boys.

$MRNA First short entry here at 225. Stop loss 227.25. Betting on a 225 rejection here. Let’s see. GL.

$MRNA usually after added to nesdaq . After official date next 2 days profit taking happen. So small dip can come. Its just heppen most of the time. I have very small position 50 shares short at 225 . Lets see.

$MRNA $SLS $MRKR Wouldn't it be funny if a junior buyer loads up on $MRKR instead of $MRK only for his boss to scream "bloody hell...u asshole! how do u mix these up? one is a multi billion company run by actual people while the other is a penny stock run by a donkey!" 😂

$MRNA Moderna went from $20/share to $500/share from 2019 to 2021. And that was because of COVID. Curing cancer? It'll be something bigger if they can pull it off.